Internal Medicine, Endocrinology, Diabetes, & Metabolism · Saint Louis, MO
NPI
1033498266
Since 2011
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
11155 Dunn Rd Ste 109n
Saint Louis, MO, 63136
Phone (314) 953-8799
Groups this clinician bills Medicare through
Medicare paid, 2024
$156K
5,353 services
Medicare patients, 2024
470
Average age 73
Drug cost, 2024
$2.1M
4,590 prescriptions
Company payments, 2025
$76.94
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rabia Asghar was code J0897 (injection, denosumab, 1 mg), 3,840 times for 38 patients. In total Rabia Asghar billed 5,353 services in 26 codes, and Medicare paid $156K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,840 | 38 | $20.56 | $79K |
| 99214 Office E&M - Established | Office | 461 | 311 | $89.81 | $41K |
| 36415 Venipuncture Blood Collection | Office | 307 | 228 | $8.04 | $2,467 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 194 | 192 | $12.86 | $2,495 |
| 95251 Test - Miscellaneous | Office | 121 | 70 | $26.53 | $3,210 |
| 99213 Office E&M - Established | Office | 87 | 82 | $54.20 | $4,716 |
| 96372 Injection Administration | Office | 66 | 41 | $9.91 | $654 |
| 99204 Office E&M - New | Office | 55 | 55 | $104.68 | $5,757 |
| 99215 Office E&M - Established | Office | 53 | 46 | $133.12 | $7,055 |
| 99232 Hospital E&M - Subsequent | Facility | 49 | 25 | $62.31 | $3,053 |
| 83037 Blood Count | Office | 20 | 20 | $9.52 | $190 |
| 99231 Hospital E&M - Subsequent | Facility | 17 | 12 | $39.27 | $668 |
| 99223 Hospital E&M - Initial | Facility | 15 | 15 | $137.23 | $2,058 |
By year: 2022 $121K for 4,664 services; 2023 $190K for 7,477 services; 2024 $156K for 5,353 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 307 | 228 | $8.04 | $2,467 |
| 83037 Blood Count | 20 | 20 | $9.52 | $190 |
Medicare prescription drug claims, 2024
In 2024, the drug Rabia Asghar prescribed most often to Medicare patients was Lantus Solostar (Insulin Glargine,hum.Rec.Anlog), with 343 prescriptions and refills. In total Rabia Asghar wrote 4,590 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 343 | 876 | 114 | $50K |
| Levothyroxine Sodium Generic | 336 | 892 | 83 | $3,172 |
| Alendronate Sodium Generic | 262 | 638 | 71 | $1,793 |
| Ozempic Semaglutide | 250 | 445 | 54 | $428K |
| Metformin Hcl Generic | 209 | 574 | 62 | $1,310 |
| Jardiance Empagliflozin | 171 | 397 | 44 | $228K |
| Glipizide Generic | 155 | 414 | 42 | $2,319 |
| Metformin Hcl Er Metformin Hcl | 151 | 412 | 48 | $1,721 |
| Glipizide Er Glipizide | 149 | 367 | 45 | $1,845 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 123 | 320 | 57 | $15K |
| Novolog Flexpen Insulin Aspart | 112 | 234 | 47 | $34K |
| Trulicity Dulaglutide | 109 | 173 | 24 | $172K |
| Humalog Kwikpen U-100 Insulin Lispro | 109 | 214 | 34 | $46K |
| Januvia Sitagliptin Phosphate | 102 | 210 | 25 | $117K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 92 | 237 | 34 | $51K |
Brand drugs: 2,277 claims; generic drugs: 1,852 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rabia Asghar $76.94 ($76.94 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbott Laboratories with $44.01.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.